ClinicalTrials.gg
WithdrawnNCT00464763Updated Mar 21, 2017

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery

A Phase 3 interventional study of Dexmedetomidine and Placebo in Delirium, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Withdrawn at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Why this study was withdrawn
The incidence of post-operative delirium observed from interim blinded data in DEX-06-09 was significantly lower than the current literature in this population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing dexmedetomidine in Delirium — 16 open to participants now, 18 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Enrollment
70th of 78
0 · median 98
Started
2007
with 1 other
Phase 3
11 of 78
3 open now
Registered
4th of 78
by date
Lead sponsor
2 of 78
Hospira, now a wholly owned subsidiary of Pfizer

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 70th largest by enrollment, is one of 2 that started in 2007, is one of 11 in phase 3, and was the 4th registered.

Delirium

933 studies on the registry are indexed under Delirium; 189 are open to participants now.

Browse Delirium studies →

Open to participants now

16 of the 78 studies testing dexmedetomidine in Delirium are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 127 Delirium studies recruiting now, 99 (78%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the prevention of postoperative delirium in subjects undergoing heart valve surgery with or without coronary artery bypass surgery (CABG) using cardiopulmonary bypass (CPB).

Read the detailed description

Postoperative delirium is an acute decline in cognition and attention which is usually transient but when delirium persists, it can impact cognitive function, morbidity and mortality. Currently, there are no drugs to prevent delirium but dexmedetomidine has the potential to meet this unmet medical need.

Dexmedetomidine is currently approved for use for 24 hours in patients on ventilators in the Intensive Care Unit(ICU). This study is to determine whether or not dexmedetomidine can prevent delirium after heart surgery. Study participation will last from randomization prior to surgery, to 3 days after surgery. Dexmedetomidine will be given through an intravenous catheter beginning at sternal closure and continue throughout the stay in the ICU. Delirium will be assessed prior to surgery and for 72 hours after surgery. This assessment will consist of questions that will evaluate memory and thought process. Thirty days after surgery, questions will be asked regarding the patients feelings about their health status and hospital billing information will be collected.

03

Conditions studied

  • Delirium

Keywords

  • Mental Health
  • Neurological Disease
  • Heart Valve Repair Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 years old) male or female who will undergo elective heart valve surgery (with or without CABG and using CPB) with general anesthesia and require an overnight stay in the ICU following surgery.
  • If female, subject is non-lactating and is either:

    1. Not of , defined as for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of : oral or parenteral contraceptives, doublebarrier method, vasectomized partner, or abstinence from sexual intercourse.
  • Subject is (ASA) Physical Status II, III, or IV.
  • Subject (or subject's legally authorized representative) has voluntarily signed and dated the document approved by the Institutional Review Board (IRB).

Exclusion criteria

Exclusion Criteria:

  • Cognitive function level by (MMSE) of ≤ 20 at screening.
  • Subject has a positive CAM-ICU result for delirium at Screening.
  • Subject requires chronic anti-psychotic therapy.
  • Subject has participated in a trial with any experimental drug or experimental implantable device within 30 days prior to the study drug administration, or has ever been enrolled in this study.
  • Subject is known to be in liver failure.
  • Subject has an anticipated potential for increased intracranial pressure or an uncontrolled seizure disorder or known psychiatric illness that could confound a normal response during study assessment.
  • Subject has acute myocardial infarction, HR \<50 bpm, SBP \<90 mmHg, is hemodynamically unstable requiring systemic inotropic drugs or intra-aortic counterpulsation balloon pump within the last 72 hours.
  • Subject is anticipated to require hypothermic circulatory arrest during this surgical procedure.
  • Subject has received treatment with a α2-agonist or antagonist (within 14 days of study entry).
  • Subject for whom opiates, propofol, Dexmedetomidine or other α2-agonists are .
  • Subject has, per the investigator's judgment, a known or suspected physical or psychological dependence on an abused drug, other than alcohol.
  • Subject has any condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
  • Subject is not expected to live more than 60 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo (PBO)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who experienced any postoperative delirium up to 3 days following surgery

    The presence of postoperative delirium will be determined by the Confusion Assessment Method (CAM-ICU)

    Time frame: Postoperative period (3-days): Twice daily (6:00 - 9:00 AM and 5:00 - 8:00 PM)

Secondary outcomes

  1. Daily percentage of subjects who experienced postoperative delirium

    Time frame: At each day during 3-day postoperative delirium

  2. Duration of postoperative delirium as determined by CAM-ICU up to 3 days post surgery

    Time frame: Up to 3 days post surgery

  3. Postoperative use of all analgesics

    Time frame: During postextubation period (Approximately 3 days)

  4. Time to extubation after arrival in ICU

    Time frame: From the time of ICU arrival to the time of ICU discharge (Approximately 3 days)

  5. Length of ICU stay

    Time frame: From the time of ICU arrival to the time of ICU discharge (Approximately 3 days)

07

Study locations

11 sites
  • Loma Linda University
    Loma Linda, California 92354, United States
  • Midatlantic Cardiovascular Associates
    Towson, Maryland 21204-7582, United States
  • Genesys Cardiovascular and Thoracic Surgical Associates
    Grand Blanc, Michigan 48439, United States
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Cardiothoracic and Vascular Surgical Specialists
    Columbus, Ohio 43214, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Texas Heart Institute
    Houston, Texas 77030, United States
  • University of Virginia Health System, Dept. of Anesthesiology
    Charlottesville, Virginia 22908-0710, United States
  • Santara Norfolk General Hospital
    Norfolf, Virginia 23507, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2007
First posted
Apr 24, 2007
Start
Apr 2007
CompletionActual
Sep 2007
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00464763
First posted
Apr 24, 2007
Start date
Apr 2007
Completion
Sep 2007
Last update
Mar 21, 2017

Study contacts

Paula Bokesch, MD
study director · Hospira, now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion